source
- AstraZeneca's oral relaxin agonist shows positive phase 2b results in chronic heart failureAstraZeneca presented phase 2b data from its Luminara trial at the European Society of Cardiology Congress in Munich. The study evaluated the oral relaxin agonist AZD5462 in patients with chronic h…
- Trump announces nine voluntary drug pricing agreements with mid-size biotech firmsOn August 31, 2026, the White House announced that President Donald Trump has secured nine new voluntary drug-pricing agreements with mid-size biotechnology companies. The companies entered the de…